Bayer and Oxford Genome Sciences form breast cancer marker pact:
This article was originally published in Clinica
Bayer HealthCare has teamed up with the UK proteomics technology company, Oxford Genome Sciences (OGeS), to evaluate new biomarkers for breast cancer. OGeS will assess the candidate biomarkers - previously identified by Bayer - that may have important applications in the diagnosis and prognosis of the disease. The evaluation will be performed using OGeS' proteomics platform, in conjunction with its Oxford Genome Anatomy Project (OGAP), which is claimed to be the "world's largest proteomics database". Under the agreement, OGeS will receive programme funding from Bayer, which will also make performance-related payments on the achievement of certain milestones.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.